• Shanghai Tasly Biopharma, the biologics arm of Tasly Pharma, has filed a prospectus for a Hong Kong IPO expected to raise up to $1 billion; 
• Terns Pharma, a California-Shanghai startup, acquired greater China rights to a liver disease treatment developed by Genfit of France in a $228 million deal; 
• Novena Global Lifecare of Singapore will receive up to $20 million in a financing from Sinopharm and Cedarlake, and the three companies plan to raise as much as $150 million for a Sino-Singapore Healthcare Fund; 
• Eddingpharm in-licensed China rights to a treatment for thrombocytopenia, a side-effect of liver disease, from Shionogi of Japan; 
• China Medical System of Shenzhen acquired greater China rights for dry eye and psoriasis treatments from India's Sun Pharma; 
• dMed Biopharma of Shanghai and New York City's Target Health, both clinical stage CROs, teamed up to provide China-US clinical trial services 
• ChosenMed Technology, a Beijing medical sequencing company, will cooperate with Iowa's Integrated DNA Tech to develop pan-cancer diagnostic panels;

Trials and Approvals

• Yisheng Biopharma of Beijing was cleared to start China trials of its PIKA-based immunotherapy to treat solid tumors; 
• Wuhan's XW Labs received US Orphan Drug Designation for its lead molecule, a clinical-stage treatment for narcolepsy;
• MicroPort Orthopedics, a US division of Shanghai's MicroPort Scientific, launched the Evolution® NitrX™ Medial-Pivot Knee replacement system; 

Company News

• Johnson & Johnson announced the opening of its China life science incubator, JLABS @ Shanghai, with 31 young companies already in residence.